Current Report Filing (8-k)
03 October 2022 - 11:16PM
Edgar (US Regulatory)
0001173281
false
0001173281
2022-09-29
2022-09-29
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 29, 2022
NeuBase
Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its
Charter)
Delaware |
|
001-35963 |
|
46-5622433 |
(State
or Other Jurisdiction
of Incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
350
Technology Drive, Pittsburgh,
PA |
|
15219 |
(Address
of Principal Executive Offices) |
|
(Zip Code) |
|
(412)
763-3350 |
|
|
(Registrant’s
Telephone Number, Including Area Code) |
|
|
N/A |
|
|
(Former
Name or Former Address, if Changed Since Last Report) |
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common
Stock, par value $0.0001 per share |
NBSE |
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 ( 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 3.01. Notice of Delisting or Failure to Satisfy a
Continued Listing Rule or Standard; Transfer of Listing.
On September 29, 2022, NeuBase
Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market notifying
the Company that, because the closing bid price for its common stock has been below $1.00 per share for 30 consecutive business days,
it no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2)
requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”), and Nasdaq
Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a
period of 30 consecutive business days.
The Notice has no immediate
effect on the listing of the Company’s common stock on The Nasdaq Capital Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A),
the Company has been provided an initial compliance period of 180 calendar days, or until March 28, 2023 to regain compliance with the
Minimum Bid Price Requirement. During the compliance period, the Company’s shares of common stock will continue to be listed and
traded on The Nasdaq Capital Market. To regain compliance, the closing bid price of the Company’s common stock must meet or exceed
$1.00 per share for a minimum of ten consecutive business days during the 180 calendar day grace period.
In the event the Company is
not in compliance with the Minimum Bid Price Requirement by March 28, 2023, the Company may be afforded a second 180 calendar day grace
period. To qualify, the Company would be required to meet the continued listing requirements for market value of publicly held shares
and all other initial listing standards for The Nasdaq Capital Market, with the exception of the Minimum Bid Price Requirement. In addition,
the Company would be required to provide written notice of its intention to cure the minimum bid price deficiency during this second 180-day
compliance period by effecting a reverse stock split, if necessary.
The Company intends to
actively monitor the bid price for its common stock between now and March 28, 2023 and will consider available options to regain
compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with
the Minimum Bid Price Requirement or that the Company will otherwise be in compliance with the other listing standards for The
Nasdaq Capital Market.
Forward-Looking Statements
Except for the factual statements made herein, information contained
in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform
Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism,
satisfaction or disappointment with current prospects or future events, as well as words such as “believes,” “intends,”
“expects,” “plans” and similar expressions, or the use of future tense, identify forward-looking statements, but
their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance
and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that
the Company will meet the Minimum Bid Price Requirement during any compliance period or otherwise in the future, otherwise meet Nasdaq compliance
standards, or that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company can agree to or ultimately
meet applicable Nasdaq requirements for any such relief. Reference is also made to other factors detailed from time to time in the Company’s
periodic reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K
and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only
as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements
to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NEUBASE THERAPEUTICS, INC. |
|
(Registrant) |
|
|
Date: October 3, 2022 |
By: |
/s/ Todd P. Branning |
|
|
Todd P. Branning |
|
|
Chief Financial Officer |
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Sep 2024 to Oct 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Oct 2023 to Oct 2024